154650-22-3Relevant academic research and scientific papers
Enantioselective cross-coupling for axially chiral tetra-ortho-substituted biaryls and asymmetric synthesis of gossypol
Yang, He,Sun, Jiawei,Gu, Wei,Tang, Wenjun
, p. 8036 - 8043 (2020)
The axially chiral tetra-ortho-substituted biaryl skeleton exists in numerous biologically important natural products, pharmaceutical molecules, chiral catalysts, and ligands. The efficient synthesis of chiral tetra-ortho-substituted biaryl structures rem
Preparation method of imidazoline pyridine compound intermediate
-
Paragraph 0085-0091; 0139-0144; 0184-0189; 0229-0234; ..., (2021/07/01)
The invention discloses a preparation method of an imidazoline pyridine compound intermediate. According to the method, a compound 2-halo-4-fluorophenyl alkyl ether in a formula 1 is used as a raw material, and is subjected to eight steps of reaction including substitution, deprotection, substitution, reduction, upper protection, ring closing, deprotection and ammonification to obtain a key intermediate of an imidazoline pyridine compound in a formula 10; and a brand new furan ring construction technology is involved in a synthesis route, the technical route is novel, isomer generation is avoided, operation is easy and convenient, purification is easy, and the method is suitable for industrial large-scale production.
QUINOXALINE DERIVATIVES
-
Page/Page column 95; 96, (2021/07/24)
The present invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS
-
Paragraph 0777, (2020/10/09)
The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.
COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE
-
Paragraph 0613-0614, (2016/04/09)
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of IDO, and for the treatment of IDO-related disorders.
